MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice

Fernandes, M; Hoggard, B; Jamme, P; Paget, S; Truong, MJ; Gregoire, V; Vinchent, A; Descarpentries, C; Morabito, A; Stanislovas, J; Farage, E; Meneboo, JP; Sebda, S; Bouchekioua-Bouzaghou, K; Nollet, M; Humez, S; Perera, T; Fromme, P; Grumolato, L; Figeac, M; Copin, MC; Tulasne, D; Cortot, AB; Kermorgant, S; Kherrouche, Z

Kherrouche, Z (通讯作者)，Univ Lille, Inst Pasteur Lille, UMR9020, CNRS,INSERM,CHU Lille,UMR1277 Canther, 1 Rue Pr Calmette,CS 50447, F-59021 Lille, France.

MOLECULAR ONCOLOGY, 2023; 17 (11): 2257

Abstract

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3-4% of non-small-cell lung cancer (......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索